Trial Profile

A RANDOMISED CONTROL STUDY TO COMPARE EFFICACY AND SAFETY OF APREMILAST AND METHOTREXATE IN PATIENTS OF PALMOPLANTAR PSORIASIS

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 17 Mar 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Apremilast (Primary) ; Folic acid; Methotrexate
Indications Palmoplantar pustulosis; Psoriasis
Focus Adverse reactions; Therapeutic Use

Most Recent Events

12 Mar 2021 Primary endpoint (change in m-PPPASI score from baseline after 16 weeks of treatment) has been met, as per results published in the American Journal of Clinical Dermatology.
12 Mar 2021 Results published in the American Journal of Clinical Dermatology
30 Jun 2020 Status changed from recruiting to completed.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com